

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Hong Kong Life Sciences and Technologies Group Limited**

**香港生命科學技術集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8085)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PLACING OF NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement of Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) dated 21 December 2016 (the “**Announcement**”) in relation to the Placing under general mandate. Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless defined otherwise herein.

As at the date of this announcement, the Company has been advised by the Placing Agent that it has procured two potential Placees. The names and information of the Placees are as follows:

1. Pacific Fortune Global Limited, a company incorporated in the British Virgin Islands with limited liability and is engaged in investment activities; and
2. Global High Growth Industries Fund Series SPC, is a Cayman Islands exempted segregated portfolio company incorporated with limited liability on 13 February 2014 to operate as a private investment funds, subscribed for the account of Shengyuan China Dragon Cutting Edge Technology Investment Fund SP.

The Completion is conditional upon the GEM Listing Committee granting to the Company the approval for the listing of, and permission to deal in, the Placing Shares. The Company will make further announcement for the Completion.

By order of the Board  
**Hong Kong Life Sciences and Technologies Group Limited**  
**Lu Zhiqiang**  
*Executive Director and Chief Executive Officer*

Hong Kong, 23 December 2016

*As at the date of this announcement, the Board comprises (i) five executive Directors, namely Mr. David Lin Kao Kun, Mr. Lu Zhiqiang, Mr. Chui Kwong Kau, Mr. Jiang Hongqing and Ms. Li Mei; (ii) one non-executive Director, namely Ms. Lam Kuo; and (iii) three independent non-executive Directors, namely Mr. Hung Yat Ming, Mr. Chan Yun Hing and Mr. Gui Qiangfang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement in this announcement misleading.*

*This announcement will remain on the “Latest Company Announcement” page of the GEM website at <http://www.hkgem.com> for seven days after the date of publication and on the website of the Company at <http://www.hklifesciences.com>.*